Tumor-Infiltrating Lymphocytes (TILs) are a type of immune cell that moves from a patient’s bloodstream into their tumor. TILs include T cells and B cells and are powerful weapons in battling cancer, as they are able to recognize and kill cancer cells. In cancer treatment, TILs are removed from a patient’s tumor, grown in large numbers in a laboratory, and injected back into the patient to help their immune system kill their cancer cells. Currently, TILs are an experimental cell therapy being developed for treating solid tumors. They have been observed to offer a strong prognostic benefit for tumor types that have so far respond poorly to immunotherapy.
ACCC has launched an education project to help members of the multidisciplinary cancer care team better understand TILs and their potential in cancer therapy. The project, which will assemble an expert task force and include a podcast and webinar, will provide general education about TIL therapy, how it works, and its potential to positively impact patient outcomes.
For more information on this project, please contact the ACCC Provider Education department.
This project is supported by Iovance Biotherapeutics.
